Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TWST
HOLDTwist Bioscience Corporation · Healthcare · United States · $5.6B · Avg Vol: $159M/d
COMPANY DESCRIPTION
Twist Bioscience Corporation is a leading synthetic biology company providing high-quality, custom DNA products for a wide range of applications, including drug discovery, diagnostics, and data storage. The company's proprietary silicon-based DNA writing platform enables the rapid, high-throughput, and cost-effective synthesis of DNA, offering a significant technological advantage over traditional methods. Its unique manufacturing process establishes a strong competitive moat in the synthetic biology market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 203.6M | 245.1M | 313.0M | 376.6M | 22.8% | 409.5M | 444.7M | 520.0M | 17.5% |
| EPS | -4.04 | -3.60 | -3.60 | -1.30 | — | -1.23 | -0.77 | -0.85 | — |
| Shares | 56.5M | 57.6M | 58.9M | 60.6M | +7.3% | 62.3M | — | — | — |
| Debt | 94.9M | 94.1M | 85.0M | 75.6M | -7.3% | 110.8M | — | — | — |
| Equity | 789.4M | 623.4M | 472.7M | 473.0M | -15.7% | — | — | — | — |
| Op CF | -124.4M | -142.5M | -64.1M | -47.6M | — | -55.6M | — | — | — |
| Inv CF | -232.9M | 50.6M | -3.1M | -24.8M | — | — | — | — | — |
| Fin CF | 270.5M | 0.9M | 6.9M | 28.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TWST are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TWST | Twist Bioscience Corporation(you) | $5.6B | 44 | HOLD |
| BLLN | BillionToOne, Inc. | $5.8B | 41 | HOLD |
| ADPT | Adaptive Biotechnologies Corporation | $3.6B | 44 | HOLD |
| RDNT | RadNet, Inc. | $4.8B | 31 | SELL |
| NEO | NeoGenomics, Inc. | $1.8B | 45 | HOLD |
| SHC | Sotera Health Company | $4.9B | 66 | BUY |
| GH | Guardant Health, Inc. | $19.5B | 47 | HOLD |
| RVTY | Revvity, Inc. | $12.3B | 64 | HOLD |
| GRAL | GRAIL, Inc. | $2.9B | 19 | STRONG SELL |
| CRL | Charles River Laboratories International, Inc. | $10.9B | 69 | BUY |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%